Christians Entrepreneurs Cell Group
A group of Christians men praising God.

By: MrEfrainlh1

Excerpt from:
Christians Entrepreneurs Cell Group - Video

Recommendation and review posted by Bethany Smith

The medical and human drama of the T-cell therapy, developed at the University of Pennsylvania, is unfolding in ways the defy the staid traditions of scientific research. On Monday, the New England Journal of Medicine fast-tracked online publication of a paper about Children's first two pediatric patients. But those results - and more - have been out for months, released by the researchers at a conference, or by the families.

The first pediatric patient, Emily Whitehead, 7, of Phillipsburg, Pa., who remains in remission after almost dying, was the subject of worldwide headlines in December.

And last week, the larger story - the harnessing of the immune system to fight cancer after decades of trying - broadened beyond Penn and Children's.

Researchers at Memorial Sloan-Kettering Cancer Center in New York published results from five adult leukemia patients treated with an experimental T-cell therapy much like Penn's. Three of them have been in remission for up to two years; one went into remission but died of a blood clot; and one relapsed and died.

Penn's therapy has worked in adults, too, but those seven patients, who had complete or partial remissions, had a less aggressive form of the disease called chronic myelogenous leukemia.

Sloan-Kettering's results are very impressive, Penn researcher David Porter said.

Penn's team, led by Carl June, will soon collaborate with Sloan-Kettering to see which version of the T-cell therapy works better, Porter said.

The two groups use slightly different viral "vectors" to deliver a therapeutic gene into the T cells. That gene programs the T cells to recognize and kill B cells, the blood component that turns malignant in the leukemias.

"One of the issues is how much does the vector contribute to the patient's response," Porter said. "So we'll trade vectors, then give patients T cells made from both vectors."

Penn is also adapting its T-cell therapy to treat solid tumors such as ovarian cancer. Meanwhile, the early success - although in a small number of patients - is stimulating the field of immunotherapy.

View post:
Parents and Children's Hospital researchers await results on an experimental leukemia gene therapy

Recommendation and review posted by Bethany Smith

WITHIN just eight days of starting a novel gene therapy, David Aponte's "incurable" leukaemia had vanished. For four other patients, the same happened within eight weeks, although one later died from a blood clot unrelated to the treatment, and another after relapsing.

The cured trio, who were all previously diagnosed with usually fatal relapses of acute lymphoblastic leukaemia, have now been in remission for between 5 months and 2 years. Michel Sadelain of the Memorial Sloan-Kettering Cancer Center in New York, co-leader of the group that designed the trial, says that a second trial of 50 patients is being readied, and the team is looking into using the technique to treat other cancers.

The key to the new therapy is identifying a molecule unique to the surface of cancer cells, then genetically engineering a patient's immune cells to attack it.

In acute lymphoblastic leukaemia, immune cells called B-cells become malignant. The team were able to target a surface molecule known as CD19 that is only present on B-cells. Doctors extracted other immune cells called T-cells from the patients. These were treated with a harmless virus, which installed a new gene redirecting them to attack all cells bearing CD19. When the engineered T-cells were reinfused into the patients, they rapidly killed all B-cells, cancerous or otherwise.

"The stunning finding was that in all five patients, tumours were undetectable after the treatment," says Sadelain.

He reckons that the body should replenish the immune system with regular T-cells and healthy B-cells after a couple of months. However, the patients received donated bone marrow to ensure they could regrow a healthy immune system (Science Translational Medicine, doi.org/kwz).

The treatment is not the first to re-engineer T-cells to attack a form of leukaemia. Last year, an international company called Adaptimmune used the approach to treat 13 people with multiple myeloma it left 10 in remission.

"Although it's early days for these trials, the approach of modifying a patient's T-cells to attack their cancer is looking increasingly like one that will, in time, have a place alongside more traditional treatments," says Paul Moss of Cancer Research UK.

Sadelain's team is now investigating the scope for attacking other cancers. Where no single surface molecule is unique to a cancer, he is seeking to target pairs of molecules that only occur together on cancer cells. In January, he demonstrated this approach by wiping out human prostate tumours implanted in mice, using T-cells engineered to target two surface molecules (Nature Biotechnology, doi.org/kw2).

If you would like to reuse any content from New Scientist, either in print or online, please contact the syndication department first for permission. New Scientist does not own rights to photos, but there are a variety of licensing options available for use of articles and graphics we own the copyright to.

See the original post here:
Gene therapy cures leukaemia in eight days

Recommendation and review posted by Bethany Smith

Public release date: 25-Mar-2013 [ | E-mail | Share ]

Contact: Clare LaFond clareh@uw.edu 206-685-1323 University of Washington - Health Sciences/UW News, Community Relations & Marketing

In an animal study, researchers at the University of Washington show that it was possible to use gene therapy to boost heart muscle function. The finding suggests that it might be possible to use this approach to treat patients whose hearts have been weakened by heart attacks and other heart conditions.

Led by University of Washington (UW) Professor and Vice Chair of Bioengineering Michael Regnier and Dr. Chuck Murry, director of the Center for Cardiovascular Biology and co-director of the Institute for Stem Cell and Regenerative Medicine at UW, the study appears online today in the journal Proceedings of the National Academy of Sciences (PNAS).

Normally, muscle contraction is powered by a molecule, the nucleotide called Adenosine-5'-triphosphate (ATP). Other naturally occurring nucleotides can also power muscle contraction, but, in most cases, they have proven to be less effective than ATP.

In an earlier study of isolated muscle, however, Regnier, Murry and colleagues had found that one naturally occurring molecule, called 2 deoxy-ATP (dATP), was actually more effective than ATP in powering muscle contraction, increasing both the speed and force of the contraction, at least over the short-term.

In the new PNAS study, the researchers wanted to see whether this effect could be sustained. To do this, they used genetic engineering to create a strain of mice whose cells produced higher-than-normal levels of an enzyme called Ribonucleotide Reductase, which converts the precursor of ATP, adenosine-5'-diphosphate or ADP, to dADP, which, in turn, is rapidly converted to dATP.

"This fundamental discovery, that dATP can act as a 'super-fuel' for the contractile machinery of the heart, or myofilaments, opens up the possibility to treat a variety of heart failure conditions," Regnier said. "An exciting aspect of this study and our ongoing work is that a relatively small increase in dATP in the heart cells has a big effect on heart performance."

The researchers found that increased production of the enzyme Ribonucleotide Reductase increased the concentration of dATP within heart cells approximately tenfold, and even though this level was still less than one to two percent of the cell's total pool of ATP, the increase led to a sustained improvement in heart muscle function, with the genetically engineered hearts contracting more quickly and with greater force.

"It looks as though we may have stumbled on an important pathway that nature uses to regulate heart contractility," Murry added. "The same pathway that heart cells use to make the building blocks for DNA during embryonic growth makes dATP to supercharge contraction when the adult heart is mechanically stressed."

See the article here:
Gene therapy may aid failing hearts

Recommendation and review posted by Bethany Smith

Stem Cell Therapy Cures Paralyzed Vet

By: TheVideOHM

More:
Stem Cell Therapy Cures Paralyzed Vet - Video

Recommendation and review posted by simmons

By Amads Ma. Guerrero Philippine Daily Inquirer

INFORMATION booth

You feel like you have entered an attractive boutique hotel in miniature; everything is neat, clean, almost spotless and sparkling.

This is the Asian Aesthetic Center in Katipunan Avenue, Quezon City (contact number: 7099565) across the Ateneo de Manila. The equipment is state-of-the-art, and there are two main wings: The Dermatology Wing and the Surgical Wing.

In the Dermatology Wing we have a Laser Room, Slimming Room, a Wellness Room and a Facial Treatment Room. The Surgical Room was what interested me mostbut only as a writer and not personally, because my cells are not dysfunctional (to my knowledge!).

Unfortunately, colleague Neilsen and I could not enter the Surgical Wing because a procedure was under way. In this wing, we were told, is a stem cell laboratory unit with the stem cell extractor and activator machines, and a recovery room, along with other amenities.

The clinic is cozy and family-run, you might say. It is headed by Dr. Amy B. Tinaza, a cosmetic surgeon and a stem cell specialist, and her partner (professional as well as personal) Dr. Jomar S. Tinaza, chief facial plastic surgeon and her husband. And the centers PR is a sister in law, Charlotte Tinaza.

The Tinaza couple head the Stem Cell Therapy Team, and there are also Medical, Surgical, Specialist and After-Care Teams.

So why did she (Dr. Amy) choose to be a stem cell specialist? Although stem cell therapy is at an early stage, I believe it is the future of medicine, she replies.

The centers stem cell therapy is the Autologous Fat Stem Cell, in which the stem cell is from the fat cells of the same patient, and transferred back to the patient once the stem cell is activated.

Read the rest here:
Stem cell therapy –how profitable?

Recommendation and review posted by simmons

ICBR: Cell Therapy
Judi Smith describes what cell therapy is and how it benefits people as well as the three locations where cell therapy is offered by the International Clinic...

By: Ryan Elliott

Read the rest here:
ICBR: Cell Therapy - Video

Recommendation and review posted by Bethany Smith

Retina Consultants of Southwest Florida

Dr. Ashish Sharma of Retina Consultants of Southwest Florida conducts an eye exam.

The Naples seminar will be from 1 p.m. to 4 p.m. at the Hilton Naples, 5111 U.S. 41 North.

An identical seminar in Fort Myers will be Monday from 9 a.m. to noon at Harborside Convention Center, 1375 Monroe St.

To register to attend, call 1-866-946-6824, or go to http://www.MassEyeAndEar.organization/symposium.

NAPLES Leonard Klein plays tennis and bridge, and both of his games could improve if he has stem cell therapy some day.

The 80-year-old suffers from dry macular degeneration. While his vision loss hasnt worsened in recent months, theres no telling the future.

Studies are under way to see if stem cell therapy can reverse vision loss for people suffering from age-related macular degeneration.

Klein will sign up if such a study opens up to Southwest Florida.

Im a risk taker and always have been, he said recently, before heading to a bridge game in the care center at the Vi at Bentley Village, a continuing care retirement community in North Naples.

View post:
Naples seminar to look at stem cell therapy to aid macular degeneration

Recommendation and review posted by Bethany Smith

Mar. 22, 2013 The notion that each gene can only codify for a single protein has been challenged for some years. Yet, the functional outcomes that may result from genes encoding more than one protein are still largely unknown. Now, in a study published in the latest issue of The Plant Cell journal, a group of scientists led by Paula Duque at the Instituto Gulbenkian de Cincia (IGC, Portugal) discovered a gene -- ZIFL1 -- that has the particularity of producing two different proteins with completely distinct locations and functions in the plant. The researchers observed that in the root ZIFL1 codifies a protein that is important for the transport of auxin, a hormone essential for the correct growth and development of the plant. However, in the leaves the same gene originates a protein that promotes tolerance to drought. The gene presented in this study is one of the few identified to produce two proteins with such different biological roles.

ZIFL1 belongs to a family of transporter genes known to be present in all classes of organisms, but the functional role of most of its members remains unknown. What is known is that these transporter genes encode proteins that are integrated into cell membranes and act by allowing the passage of small molecules across them. By undergoing genetic and cell biology studies in the plant model Arabidopsis thaliana, Paula Duque's team was able to study the role of the ZIFL1 gene. What surprised the scientists was that mutant plants unable to produce the ZIFL1 transporter presented specific defects in different organs and functions. On one hand, their roots exhibited problems of growth, ramification and orientation when compared to normal plants.

These observations suggested that the ZIFL1 gene was involved in the transport of the auxin hormone, which plays an important role in the development of the root. But the researchers also found out that the mutant plants had problems in tolerating drought. They realized that the leaf pores that regulate transpiration -- the stomata -- were more open in the mutants than in normal plants, resulting in the loss of higher quantities of water. This suggested a role for ZIFL1 in the closure of stomata and in the control of water loss by the plant, which can be critical under drought conditions.

Intrigued by these observations, the researchers investigated whether the ZIFL1 gene could be originating two proteins that would act differently in distinct tissues. Alternative splicing is a key mechanism allowing the same gene to produce multiple proteins. When genes are activated to give rise to proteins, they first originate an intermediate molecule of RNA that can be processed differently, with some parts being removed. This cut and paste process may originate different RNA molecules that can then be converted into different proteins. Estelle Remy, investigator at Duque's laboratory and first author of this work, observed that in the case of the ZIFL1 gene, alternative splicing originates two RNA molecules that differ in just two chemical residues. However, this small difference has a huge impact on the proteins that are generated, with one of them being shortened by 67 amino acids. In collaboration with Isabel S-Correia's group at Instituto Superior Tcnico, the researchers then tested the activity of the two proteins in yeast cells and found that both transport potassium ions.

Having different size but similar transport activity, Estelle looked for the reason why these two proteins had such distinct biological functions. Surprisingly, she observed that root tissues only present the longer form of the protein, whereas the shorter protein can only be found in the leaves. Furthermore, the location of these two proteins also differs inside the cells of the root and leaves, being integrated into different cell membranes. According to Estelle, "the fact that we cannot find both proteins being expressed either in roots or leaves suggests that these tissues may have specific factors that somehow influence the splicing of the ZIFL1 RNA into the form that confers the biological role necessary for that tissue."

Says Paula Duque, "To our knowledge, there are not many known cases of proteins with such different biological functions being codified by the same gene. What is most fascinating is how the inclusion or removal of just two chemical residues in the RNA molecule results in the production of two proteins that play essential roles either in hormone transport or in tolerance to drought."

Alternative splicing is a crucial mechanism to generate protein diversity. In humans, about 20,000 to 25,000 genes codify proteins. However, recent studies indicate that over 90% of these genes undergo alternative splicing, with scientists estimating that there may be up to 500,000 or more different proteins in the human body.

This study was carried out at the IGC in collaboration with the research groups of Isabel S-Correia (Biological Sciences Research Group, IBB/CEBQ, Instituto Superior Tcnico, Portugal) and Ji Friml (VIB/Ghent University, Belgium and Institute of Science and Technology, Austria). It was funded by Fundao para a Cincia e a Tecnologia (Portugal).

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Read the original here:
When a gene is worth two: Same gene fulfills different biological roles in plants

Recommendation and review posted by Bethany Smith

Philosophy of music.

By: Eric Bottelberghe

See original here:
Philosophy of music. - Video

Recommendation and review posted by Bethany Smith

KORBANI STYLE-Gangnam Style in Bangali(Official)
Korbani Style!!! This is the official video #39;Kurbani Style #39; that is the remake of the famous music video Gangnam Style Please enjoy!.

By: EFAZTHEGREAT

Read the original:
KORBANI STYLE-Gangnam Style in Bangali(Official) - Video

Recommendation and review posted by Bethany Smith

AppTalk: web vs hybrid vs native apps
Speaker: Sebastian de Mel. The content starts at 31:11 See https://www.facebook.com/techclubtampere for more information.

By: Karl Ots

Go here to read the rest:
AppTalk: web vs hybrid vs native apps - Video

Recommendation and review posted by Bethany Smith

Vsauce - Can You Boomerang A Football?
Can you boomerang a football? Michael Stevens, creator of Vsauce, along with Steve Roberts from STRskillSchool finds out. Subscribe to Copa90: http://bit.ly/...

By: Copa90

Read the original here:
Vsauce - Can You Boomerang A Football? - Video

Recommendation and review posted by Bethany Smith

plants and their environments for technology

By: Zach Stone

Here is the original post:
plants and their environments for technology - Video

Recommendation and review posted by Bethany Smith

Living healthy in a fallen world
The course cover the core principles of a healthy christian life.

By: Mark Dailey

Read the rest here:
Living healthy in a fallen world - Video

Recommendation and review posted by Bethany Smith

Billy Corgan: Total Paradigm Shift
Smashing Pumpkins founder and lead singer Billy Corgan joined Alex Jones once again in studio for a powerful interview. In this excerpt, Corgan analyzes the ...

By: TheAlexJonesChannel

Here is the original post:
Billy Corgan: Total Paradigm Shift - Video

Recommendation and review posted by Bethany Smith

Nazi American Proof pt 2
This is proof nazi #39;s have taken over. This is by Dr. Phil Valentine video= The art and science of hyper dimensional warfare!!! Stop by my channel Subscribe!!!

By: wally810ft

Read more:
Nazi American Proof pt 2 - Video

Recommendation and review posted by Bethany Smith

When is a fish not a fish but a drug? When government regulators take old laws and twist themselves into knots trying to apply them to new technology.

In the emotionally charged battle over the safety and appropriateness of genetically modified foods, people on both sides agree that the way the government oversees genetically modified plants and animals is patchy, inconsistent and at times just plain bizarre.

Soon, analysts say, the system may be stretched to the breaking point. That could leave many genetically modified crops unregulated a worry for those who fear environmental and safety risks or who believe that government vetting is key for broad public acceptance.

"It's a bit of a mess," said Jennifer Kuzma, a science policy expert at the Humphrey School of Public Affairs at the University of Minnesota.

The web of regulations used to govern genetically engineered species draws on more than 10 laws, all written for other purposes. Some were crafted to address issues such as tainted drugs, wheat spiked with sawdust and pollution by industrial chemicals.

The results can be odd.

Atlantic salmon that grow quickly thanks to a growth hormone gene from another salmon species are deemed "new animal drugs" because the Food and Drug Administration decided to regulate genetically engineered animals under the Food, Drug and Cosmetic Act of 1938.

A cotton plant that makes insect-killing proteins with the help of a gene from a soil bacterium is a pesticide in the eyes of the Environmental Protection Agency, which regulates the crop under the Federal Insecticide, Fungicide and Rodenticide Act of 1972.

In what some critics deem the biggest contortion, many genetically modified crops are classified as "potential plant pests" so that the U.S. Department of Agriculture may preside over them through the Federal Plant Pest Act of 1957 even though the key traits added to the plants have nothing to do with pests.

Some crops are regulated by more than one agency: A corn plant engineered to kill insects, for example, is reviewed by the EPA and USDA and also gets a voluntary assessment from the FDA.

Read more:
Genetic modification strains old food and drug laws

Recommendation and review posted by Bethany Smith

Jim W Dean Israel Partners in War Crimes

By: Gordon Duff

The rest is here:
Jim W Dean Israel Partners in War Crimes - Video

Recommendation and review posted by Bethany Smith

Public release date: 24-Mar-2013 [ | E-mail | Share ]

Contact: Les Lang llang@med.unc.edu 919-966-9366 University of North Carolina Health Care

CHAPEL HILL, N.C. Every time a cell divides it makes a carbon copy of crucial ingredients, including the histone proteins that are responsible for spooling yards of DNA into tight little coils. When these spool-like proteins aren't made correctly, it can result in the genomic instability characteristic of most birth defects and cancers.

Seven years ago, Dr. Joe Gall of the Carnegie Institute in Baltimore, Md. and coworkers noticed an aggregation of molecules along a a block of genome that codes for the critical histones, but they had no idea how this aggregate or "histone locus body" was formed.

Now, research conducted in fruit flies at the University of North Carolina School of Medicine has pinpointed a specific DNA sequence that both triggers the formation of this "histone locus body" and turns on all the histone genes in the entire block.

The finding, published March 25, 2013 in the journal Developmental Cell, provides a model for the coordinated synthesis of histones needed for assembly into chromatin, a process critical to keeping chromosomes intact and passing genetic information from generation to generation.

"Our study has uncovered a new relationship between nuclear architecture and gene activity," said senior study author Bob Duronio, PhD, professor of biology and genetics at UNC. "In order to make chromosomes properly, you need to make these histone building blocks at the right time and in the right amount. We found that the cell has evolved this complex architecture to do that properly, and that involves an interface between the assembly of various components and the turning on of a number of genes."

In the fruit fly, as in the human, the five different histone genes exist in one long chunk of the genome. The "histone locus" in flies contains 100 copies of each of the five genes, encompassing approximately 500,000 nucleotides of A's, C's, T's and G's. The proteins required for making the histone message a process that must happen every time a new strand of DNA is copied come together at this "histone locus" to form the "histone locus body."

Duronio and co-senior study author William Marzluff, PhD, Kenan Distinguished Professor of Biochemistry and Biophysics, wanted to figure out how these factors knew to meet at the histone locus.

They inserted different combinations of the five histone genes into another site of the genome, and looked to see which combinations recruited a new histone locus body. The researchers found that combinations that contained a specific 300 nucleotide sequence the region between the H3 and H4 histone genes formed a histone locus body. In contrast, combinations of genes that lacked this sequence did not form the body. They went on to show that this sequence turned on not only the H3 and H4 genes in its direct vicinity, but also other histone genes in the block.

Read more:
Researchers identify genetic sequence that helps to coordinate synthesis of DNA-packaging proteins

Recommendation and review posted by Bethany Smith

Biotech Vlog - Gene Therapy
A Biotech vlog on Gene Therapy that I did for a school assignment.

By: dkhl65

See the article here:
Biotech Vlog - Gene Therapy - Video

Recommendation and review posted by Bethany Smith

OMICS Publishing Group- Journal of Genetic Syndromes Gene Therapy
OMICS Publishing Group, Journal of Genetic Syndromes and Gene Therapy under Open Access Category conveys the latest research information on identification an...

By: OMICSPublishingGroup

Here is the original post:
OMICS Publishing Group- Journal of Genetic Syndromes

Recommendation and review posted by Bethany Smith

Journal of Genetic Syndromes Gene Therapy | OMICS Publishing Group
OMICS Publishing Group , Journal of Genetic Syndromes Gene Therapy is an international, peer-reviewed scientific journal emphasizes the documentation of ph...

By: OMICSPublishingGroup

Visit link:
Journal of Genetic Syndromes

Recommendation and review posted by Bethany Smith

Controlling Blood Loss in Laparoscopic Liver Pancreas Surgery Using the Aquamantys® System
Please join us on April 9th, 2013 at 7pm EDT as Michael House, MD Michael House, MD, from the Indiana University Health share their perspective on the use ...

By: ORLivedotcom

Visit link:
Controlling Blood Loss in Laparoscopic Liver

Recommendation and review posted by Bethany Smith

The Vaccine Gene Therapy Institute of Florida corporateroadshow.com
Watch Keith Knutson talk about how Tapimmune (tpiv) fits into the institutes program.

By: Frank Ferraro

Originally posted here:
The Vaccine

Recommendation and review posted by Bethany Smith